o\ue000 Written\ue000 communications\ue000 pursuant\ue000 to\ue000 Rule\ue000 425\ue000 under\ue000 the\ue000 Securities\ue000 Act\ue000 (17\ue000 CFR\ue000 230.425)
o\ue000 Soliciting\ue000 material\ue000 pursuant\ue000 to\ue000 Rule\ue000 14a-12\ue000 under\ue000 the\ue000 Exchange\ue000 Act\ue000 (17\ue000 CFR\ue000 240.14a-12)
o\ue000 Pre-commencement\ue000 communications\ue000 pursuant\ue000 to\ue000 Rule\ue000 14d-2(b)\ue000 under\ue000 the\ue000 Exchange\ue000 Act\ue000 (17\ue000 CFR\ue000 240.14d-2(b))
o\ue000 Pre-commencement\ue000 communications\ue000 pursuant\ue000 to\ue000 Rule\ue000 13e-4(c)\ue000 under\ue000 the\ue000 Exchange\ue000 Act\ue000 (17\ue000 CFR\ue000 240.13e-4(c))

Ex-5.1\ue000 Opinion\ue000 of\ue000 Mintz,\ue000 Levin,\ue000 Cohn,\ue000 Ferris,\ue000 Glovsky\ue000 and\ue000 Popeo,\ue000 P.C.
Ex-10.1\ue000 Placement\ue000 Agent\ue000 Agreement,\ue000 dated\ue000 February\ue000 19,\ue000 2009.
Ex-10.2\ue000 Form\ue000 of\ue000 Warrant\ue000 to\ue000 purchase\ue000 shares\ue000 of\ue000 ARIAD\ue000 Pharmaceuticals,\ue000 Inc.\ue000 common\ue000 stock.
Ex-10.3\ue000 Form\ue000 of\ue000 Subscription\ue000 Agreement\ue000 between\ue000 ARIAD\ue000 Pharmaceuticals,\ue000 Inc.\ue000 and\ue000 each\ue000 of\ue000 the\ue000 purchasers.

Markets\ue000 LLC\ue000 (the\ue000 \u2018\u2018Placement\ue000 Agent\u2019\u2019),\ue000 relating\ue000 to\ue000 the\ue000 sale\ue000 by\ue000 the\ue000 Company\ue000 of\ue000 14,378,698\ue000 shares\ue000 of\ue000 common\ue000 stock\ue000 (approximately\ue000 19.9%\ue000 of\ue000 the
Company\u2019s\ue000 outstanding\ue000 common\ue000 shares)\ue000 at\ue000 a\ue000 purchase\ue000 price\ue000 of\ue000 $1.69\ue000 per\ue000 share.\ue000 Investors\ue000 also\ue000 received\ue000 0.75\ue000 of\ue000 a\ue000 warrant\ue000 for\ue000 each\ue000 share\ue000 of
common\ue000 stock.\ue000 The\ue000 warrants\ue000 have\ue000 a\ue000 three-year\ue000 term\ue000 from\ue000 the\ue000 date\ue000 of\ue000 issuance,\ue000 are\ue000 exercisable\ue000 beginning\ue000 six\ue000 months\ue000 after\ue000 the\ue000 date\ue000 of\ue000 issuance
and\ue000 will\ue000 be\ue000 exercisable\ue000 at\ue000 a\ue000 price\ue000 of\ue000 $2.15\ue000 per\ue000 share.\ue000 The\ue000 Placement\ue000 Agent\ue000 Agreement,\ue000 the\ue000 form\ue000 of\ue000 Warrant\ue000 and\ue000 the\ue000 form\ue000 of\ue000 Subscription
Agreement\ue000 pursuant\ue000 to\ue000 which\ue000 the\ue000 Company\ue000 sold\ue000 and\ue000 issued\ue000 the\ue000 shares\ue000 and\ue000 warrants\ue000 to\ue000 the\ue000 investors\ue000 are\ue000 filed\ue000 as\ue000 Exhibits\ue000 10.1,\ue000 10.2\ue000 and\ue000 10.3,
respectively,\ue000 to\ue000 this\ue000 Current\ue000 Report\ue000 on\ue000 Form\ue000 8-K\ue000 and\ue000 such\ue000 documents\ue000 are\ue000 incorporated\ue000 herein\ue000 by\ue000 reference.\ue000 The\ue000 net\ue000 proceeds\ue000 to\ue000 the\ue000 Company
from\ue000 the\ue000 sale\ue000 of\ue000 the\ue000 shares\ue000 and\ue000 warrants,\ue000 after\ue000 deducting\ue000 the\ue000 fees\ue000 of\ue000 the\ue000 Placement\ue000 Agent\ue000 and\ue000 estimated\ue000 offering\ue000 expenses,\ue000 will\ue000 be
approximately\ue000 $22.8\ue000 million.\ue000 The\ue000 Company\u2019s\ue000 press\ue000 release\ue000 dated\ue000 February\ue000 20,\ue000 2009,\ue000 announcing\ue000 its\ue000 agreement\ue000 to\ue000 sell\ue000 the\ue000 shares\ue000 and\ue000 warrants\ue000 is
filed\ue000 as\ue000 Exhibit\ue000 99.1\ue000 to\ue000 this\ue000 Current\ue000 Report\ue000 on\ue000 Form\ue000 8-K,\ue000 and\ue000 the\ue000 information\ue000 contained\ue000 therein\ue000 is\ue000 incorporated\ue000 herein\ue000 by\ue000 reference.

\ue000\ue000\ue000\ue000\ue000The\ue000 shares\ue000 and\ue000 warrants\ue000 were\ue000 offered\ue000 and\ue000 sold\ue000 pursuant\ue000 to\ue000 a\ue000 prospectus\ue000 supplement\ue000 dated\ue000 February\ue000 19,\ue000 2009\ue000 and\ue000 an\ue000 accompanying prospectus\ue000 dated\ue000 February\ue000 16,\ue000 2007,\ue000 pursuant\ue000 to\ue000 the\ue000 Company\u2019s\ue000 effective\ue000 shelf\ue000 registration\ue000 statement\ue000 on\ue000 Form\ue000 S-3\ue000 (Registration\ue000 No.\ue000 333- 140333).\ue000 The\ue000 offering\ue000 is\ue000 scheduled\ue000 to\ue000 close\ue000 on\ue000 February\ue000 25,\ue000 2009,\ue000 subject\ue000 to\ue000 customary\ue000 closing\ue000 conditions.